BE1003519A3 - Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. - Google Patents
Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. Download PDFInfo
- Publication number
- BE1003519A3 BE1003519A3 BE8901089A BE8901089A BE1003519A3 BE 1003519 A3 BE1003519 A3 BE 1003519A3 BE 8901089 A BE8901089 A BE 8901089A BE 8901089 A BE8901089 A BE 8901089A BE 1003519 A3 BE1003519 A3 BE 1003519A3
- Authority
- BE
- Belgium
- Prior art keywords
- formula
- piperazine
- carbon atoms
- preparation
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000008569 process Effects 0.000 title claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 5
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title claims abstract description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title claims description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 150000004885 piperazines Chemical class 0.000 claims abstract description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 3,4,5-trimethoxy benzoyl Chemical group 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 7
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 101150041968 CDC13 gene Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- MYNRDUPGBPOWQT-IDTAVKCVSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-[[3-hydrazinylpropyl(methyl)amino]methyl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CN(CCCNN)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MYNRDUPGBPOWQT-IDTAVKCVSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- ZMYAKSMZTVWUJB-UHFFFAOYSA-N 2,3-dibromopropanoic acid Chemical compound OC(=O)C(Br)CBr ZMYAKSMZTVWUJB-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- NJOFSWSQTSPXBY-UHFFFAOYSA-N 2-bromo-2-(bromomethyl)octanamide Chemical compound C(CCCCC)C(C(=O)N)(CBr)Br NJOFSWSQTSPXBY-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- XIZPKHQGQDKOFL-UHFFFAOYSA-N C(CC)(=O)OCC(C(CCC)Br)Br Chemical compound C(CC)(=O)OCC(C(CCC)Br)Br XIZPKHQGQDKOFL-UHFFFAOYSA-N 0.000 description 1
- 0 CC(*)(C(*)C(C(C)(*)C1*)=*)C1N Chemical compound CC(*)(C(*)C(C(C)(*)C1*)=*)C1N 0.000 description 1
- LDJPDVOKFJUHRV-UHFFFAOYSA-N CC1(C(OC)=CC(C(C)=O)=CC1OC)OC Chemical compound CC1(C(OC)=CC(C(C)=O)=CC1OC)OC LDJPDVOKFJUHRV-UHFFFAOYSA-N 0.000 description 1
- KAERJIIYYUCZMB-UHFFFAOYSA-N ClC1=C(C=CC=C1)C(C(=O)N)(CBr)Br Chemical compound ClC1=C(C=CC=C1)C(C(=O)N)(CBr)Br KAERJIIYYUCZMB-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888823775A GB8823775D0 (en) | 1988-10-11 | 1988-10-11 | New 2-carbonyl substituted n n'-di-(trimethoxybenzoyl)piperazines |
| GB8823775 | 1988-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1003519A3 true BE1003519A3 (fr) | 1992-04-14 |
Family
ID=10644988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE8901089A BE1003519A3 (fr) | 1988-10-11 | 1989-10-10 | Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US4923870A (en:Method) |
| JP (1) | JPH0635452B2 (en:Method) |
| KR (1) | KR970004912B1 (en:Method) |
| AR (1) | AR245110A1 (en:Method) |
| AT (1) | AT395423B (en:Method) |
| AU (1) | AU618220B2 (en:Method) |
| BE (1) | BE1003519A3 (en:Method) |
| CA (1) | CA1320958C (en:Method) |
| CH (1) | CH679859A5 (en:Method) |
| DE (1) | DE3933881C2 (en:Method) |
| DK (1) | DK500389A (en:Method) |
| DZ (1) | DZ1365A1 (en:Method) |
| ES (1) | ES2018403A6 (en:Method) |
| FI (1) | FI96854C (en:Method) |
| FR (2) | FR2637593B1 (en:Method) |
| GB (2) | GB8823775D0 (en:Method) |
| GR (1) | GR1000343B (en:Method) |
| HK (1) | HK47592A (en:Method) |
| IE (1) | IE62011B1 (en:Method) |
| IN (1) | IN173325B (en:Method) |
| IT (1) | IT1237088B (en:Method) |
| LU (1) | LU87604A1 (en:Method) |
| MA (1) | MA21652A1 (en:Method) |
| MY (1) | MY106235A (en:Method) |
| NL (1) | NL8902520A (en:Method) |
| NO (1) | NO176180C (en:Method) |
| NZ (1) | NZ230927A (en:Method) |
| OA (1) | OA09139A (en:Method) |
| PT (1) | PT91941B (en:Method) |
| SE (1) | SE505239C2 (en:Method) |
| SG (1) | SG41292G (en:Method) |
| TN (1) | TNSN89110A1 (en:Method) |
| ZA (1) | ZA897554B (en:Method) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823776D0 (en) * | 1988-10-11 | 1988-11-16 | Scras | New 2-methoxycarbonyl sustituted n n'-di-(trimethoxybenzoyl)piperazines |
| GB8908587D0 (en) * | 1989-04-15 | 1989-06-01 | Scras Societe De Conseils De R | New 2-substituted n,n'-ditrimethoxybenzoyl piperazines |
| US5292726A (en) * | 1991-05-22 | 1994-03-08 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| US5348955A (en) * | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
| FR2780649B1 (fr) | 1998-07-06 | 2001-03-09 | Univ Paris Vii Denis Diderot | Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1243991A (en) * | 1968-06-10 | 1971-08-25 | Ici Ltd | Piperidine, morpholine and piperazine derivatives |
| DE2360545A1 (de) * | 1972-12-07 | 1974-06-12 | Degussa | Neue trialkoxyaroyldiamine |
| EP0284359A1 (en) * | 1987-03-24 | 1988-09-28 | Takeda Chemical Industries, Ltd. | 1,4-Disubstituted piperazine compounds, their production and use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3186993A (en) * | 1962-06-07 | 1965-06-01 | Ethyl Corp | alpha, alpha'-(1, 4-piperazinediyl) bis (3, 5-dialkyl-4-hydroxythiobenzaldehyde) compounds |
| DE2423847A1 (de) * | 1973-05-28 | 1975-01-02 | Ciba Geigy Ag | Neue sulfamoylbenzoesaeureamide |
| GB8427735D0 (en) * | 1984-11-02 | 1984-12-12 | Fujisawa Pharmaceutical Co | Piperazine compound |
| FR2581993B1 (fr) * | 1985-05-14 | 1988-03-18 | Synthelabo | Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique |
| DE3636278A1 (de) * | 1986-10-24 | 1988-05-05 | Hoechst Ag | Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung |
| GB8823776D0 (en) * | 1988-10-11 | 1988-11-16 | Scras | New 2-methoxycarbonyl sustituted n n'-di-(trimethoxybenzoyl)piperazines |
| US4997836A (en) * | 1988-11-11 | 1991-03-05 | Takeda Chemical Industries, Ltd. | Trisubstituted piperazine compounds, their production and use |
-
1988
- 1988-10-11 GB GB888823775A patent/GB8823775D0/en active Pending
-
1989
- 1989-09-29 CA CA000615178A patent/CA1320958C/en not_active Expired - Fee Related
- 1989-10-03 IN IN875DE1989 patent/IN173325B/en unknown
- 1989-10-04 ZA ZA897554A patent/ZA897554B/xx unknown
- 1989-10-06 CH CH3658/89A patent/CH679859A5/fr not_active IP Right Cessation
- 1989-10-06 NZ NZ230927A patent/NZ230927A/xx unknown
- 1989-10-06 US US07/418,114 patent/US4923870A/en not_active Expired - Lifetime
- 1989-10-09 GR GR890100647A patent/GR1000343B/el not_active IP Right Cessation
- 1989-10-09 SE SE8903312A patent/SE505239C2/sv not_active IP Right Cessation
- 1989-10-09 DZ DZ890157A patent/DZ1365A1/fr active
- 1989-10-10 NO NO894038A patent/NO176180C/no not_active IP Right Cessation
- 1989-10-10 AU AU42688/89A patent/AU618220B2/en not_active Ceased
- 1989-10-10 KR KR1019890014506A patent/KR970004912B1/ko not_active Expired - Fee Related
- 1989-10-10 PT PT91941A patent/PT91941B/pt not_active IP Right Cessation
- 1989-10-10 DK DK500389A patent/DK500389A/da not_active Application Discontinuation
- 1989-10-10 TN TNTNSN89110A patent/TNSN89110A1/fr unknown
- 1989-10-10 MY MYPI89001392A patent/MY106235A/en unknown
- 1989-10-10 ES ES8903410A patent/ES2018403A6/es not_active Expired - Lifetime
- 1989-10-10 AR AR89315126A patent/AR245110A1/es active
- 1989-10-10 MA MA21904A patent/MA21652A1/fr unknown
- 1989-10-10 BE BE8901089A patent/BE1003519A3/fr not_active IP Right Cessation
- 1989-10-10 LU LU87604A patent/LU87604A1/fr unknown
- 1989-10-10 IE IE325889A patent/IE62011B1/en not_active IP Right Cessation
- 1989-10-11 OA OA59663A patent/OA09139A/xx unknown
- 1989-10-11 NL NL8902520A patent/NL8902520A/nl not_active Application Discontinuation
- 1989-10-11 FR FR898913260A patent/FR2637593B1/fr not_active Expired - Lifetime
- 1989-10-11 AT AT0234689A patent/AT395423B/de not_active IP Right Cessation
- 1989-10-11 FR FR898913261A patent/FR2637500B1/fr not_active Expired - Lifetime
- 1989-10-11 JP JP1263142A patent/JPH0635452B2/ja not_active Expired - Lifetime
- 1989-10-11 IT IT02199289A patent/IT1237088B/it active IP Right Grant
- 1989-10-11 DE DE3933881A patent/DE3933881C2/de not_active Expired - Fee Related
- 1989-10-11 FI FI894812A patent/FI96854C/fi not_active IP Right Cessation
- 1989-10-11 GB GB8922870A patent/GB2223753B/en not_active Expired - Lifetime
-
1992
- 1992-04-14 SG SG412/92A patent/SG41292G/en unknown
- 1992-07-02 HK HK475/92A patent/HK47592A/xx not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1243991A (en) * | 1968-06-10 | 1971-08-25 | Ici Ltd | Piperidine, morpholine and piperazine derivatives |
| DE2360545A1 (de) * | 1972-12-07 | 1974-06-12 | Degussa | Neue trialkoxyaroyldiamine |
| EP0284359A1 (en) * | 1987-03-24 | 1988-09-28 | Takeda Chemical Industries, Ltd. | 1,4-Disubstituted piperazine compounds, their production and use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2476088A2 (fr) | Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique | |
| EP0202164A1 (fr) | Dérivés de (benzoyl-4 pipéridino)-2 phenyl-1 alcanols, leur préparation et leur application en thérapeutique | |
| FR2548666A1 (fr) | Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique | |
| EP0479631B1 (fr) | Dérivés du spiro [4.5]décane leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
| BE1003519A3 (fr) | Nouveaux derives de la carbonyl-2 n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
| EP0239461A1 (fr) | Dérivés de N-¬¬(hydroxy-2 phényl) (phényl) méthylène amino-2 éthyl acétamide, leur préparation et leur application en thérapeutique | |
| BE1007245A3 (fr) | Derives di-substitues des n, n'-ditrimethoxybenzoyle piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
| EP1001944B1 (fr) | Derives de pyrazine, leur preparation et les medicaments les contenant | |
| EP0256936A1 (fr) | Nouveaux dérivés de la benzyl-4 pipérazine, leur préparation et les compositions pharmaceutiques qui les contiennent | |
| EP0364350B1 (fr) | Dérivés de méthyl-4[(phényl-4 pipérazinyl-1)-2 éthyl]-5 thiazole, leur procédé de préparation et les compositions pharmaceutiques en contenant | |
| FR2611139A1 (fr) | Medicaments a base de nouveaux derives oxy-5 du tetrahydrofurane | |
| FR2480286A1 (fr) | Nouveaux derives de theophyllinylmethyldioxolane, leurs procedes de preparation et leur application en therapeutique | |
| BE1003518A3 (fr) | Nouveaux derives de la methoxycarbonyl-2-n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
| EP0074873A1 (fr) | Dérivés de phénoxy-3 propanol-2, leur préparation et leur application en thérapeutique | |
| FR2615735A1 (fr) | Compositions therapeutiques a base de nouveaux (o-ammonio acyloxy methylene)-5 tetrahydrofuranes et tetrahydrothiophenes | |
| EP0294258A1 (fr) | Dérivés d'hydrazine, procédé d'obtention et compositions pharmaceutiques les contenant | |
| FR2516510A1 (fr) | Derives de la (trimethoxy-3,4,5-cinnamoyl)-1-aminocarbonylethyl-4-piperazine substituee utilisables en pharmacie et procede pour leur preparation | |
| EP0347305B1 (fr) | [(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif | |
| EP0017523B1 (fr) | Nouveaux dérivés du dithiépinno (1,4)(2,3-c)pyrrole, leur préparation et les médicaments qui les contiennent | |
| EP0043811B1 (fr) | Nouvelles indolonaphtyridines et leur utilisation en tant que médicaments | |
| EP0100257B1 (fr) | Nouveaux dérivés aminoalkyl naphtaléniques, leurs sels d'addition d'acide et le procédé de préparation ainsi que l'application en thérapeutique de ces dérivés et sels | |
| FR2508032A1 (fr) | Nouveaux derives amino-3 aryloxymethyl-2 propanol-1, leur procede de preparation et leurs applications en therapeutique | |
| EP0203902A2 (fr) | Dérivés de 1,2,3,4,5,6-hexahydro-azépino[4,5-b]indole, leur préparation, composes intermédiaires, et leur application en thérapeutique | |
| EP0120741B1 (fr) | Nouveaux médicaments dérivés de la chloro-4 dithiole-1,2 one-3 et les compositions médicinales qui les contiennent | |
| FR2504141A1 (fr) | Nouveaux derives dioxazabicycliques, leur procede de preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Effective date: 20041031 |
|
| RE | Patent lapsed |
Effective date: 20041031 |